Physician profile
Robert Beck
NPI 1740284355
$170.85
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.84 · 2020: $77.01.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $39.89 | 2020 | |
| Glaxosmithkline, LLC. | $38.76 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.54 | 2019 | |
| Sanofi Pasteur INC. | $16.66 | 2019 | |
| Pfizer INC. | $16.17 | 2019 | |
| Neos Therapeutics, Lp | $13.97 | 2020 | |
| Vertical Pharmaceuticals, LLC | $10.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.